Posted from Patent Law Blog (Patently-O) 32 days ago
Patent Law : News
Please take four minutes from your day to complete the following survey on the ethics of patent prosecution: ETHICS SURVEY. This survey stems from last week’s discussion of the “Poor Man’s Opposition,” and considers how attorneys and agents should respond... (original story)
Posted from Patent Law Jobs by Patently-O 32 days ago
Patent Law : Jobs
Posted from Patent / Trademark Law News 32 days ago
Patent Law : News
LiveVox announces the U.S. Patent and Trademark Office has awarded a patent for the company's carrier-grade, hosted-VoIP-dialer solution. (original story)
Posted from Patent Law Blog (Patently-O) 32 days ago
Patent Law : News
The PTO is asking whether these numbers are accurate under the newly finalized Appeal Brief rules. (This will impact whether the Whitehouse allows the new rules to be implemented). Comments are due by August 9, 2008, to Susan Fawcett (Susan.Fawcett@uspto.gov),... (original story)
Posted from Patent Law Jobs by Patently-O 32 days ago
Patent Law : Jobs
Posted from Patent Law Blog (Patently-O) 32 days ago
Patent Law : Analysis
The PTO is asking whether these numbers are accurate under the newly finalized Appeal Brief rules. (This will impact whether the Whitehouse allows the new rules to be implemented). Comments are due by August 9, 2008, to Susan Fawcett (Susan.Fawcett@uspto.gov),... (original story)
Posted from Patent Law Blog (Patently-O) 32 days ago
Patent Law : Analysis
Please take four minutes from your day to complete the following survey on the ethics of patent prosecution: ETHICS SURVEY. This survey stems from last week’s discussion of the “Poor Man’s Opposition,” and considers how attorneys and agents should respond... (original story)
Posted from Patent Law Blog (Patently-O) 32 days ago
Patent Law : News
Hemphill v. Kimberly-Clark (Fed. Cir. 2008 — appeal pending) Over the past few years, the CAFC has been developing its jurisprudence on both claim preclusion and issue preclusion. A new appeal will likely add to the mix. Hemphill initially sued... (original story)
Posted from Patent Law Blog (Patently-O) 32 days ago
Patent Law : Analysis
Hemphill v. Kimberly-Clark (Fed. Cir. 2008 — appeal pending) Over the past few years, the CAFC has been developing its jurisprudence on both claim preclusion and issue preclusion. A new appeal will likely add to the mix. Hemphill initially sued... (original story)
Posted from Patent / Trademark Law News 33 days ago
Patent Law : News
On 15 July 2008, Slashdot had a post titled: MSM Noticing That Patent Gridlock Stunts Innovation, which includes text--> that most traditional of mainstream media, the Wall Street Journal, arguing the point ... (original story)
Posted from OUT-LAW.COM :: Patents 33 days ago
Patent Law : Analysis
Posted from Patent Law Blog (Patently-O) 33 days ago
Patent Law : News
Peer-to-patent public review of pending applications is expanding to Business Method Patents. [PTO Press Release][ http://www.peertopatent.org/ ] . Check out this calendar before planning your next DC trip – Perhaps you can work-in a visit to the CAFC while it... (original story)
Posted from Patent Law Blog (Patently-O) 33 days ago
Patent Law : Analysis
Peer-to-patent public review of pending applications is expanding to Business Method Patents. [PTO Press Release][ http://www.peertopatent.org/ ] . Check out this calendar before planning your next DC trip – Perhaps you can work-in a visit to the CAFC while it... (original story)
Posted from Patent Law Blog (Patently-O) 33 days ago
Patent Law : Analysis
Merck v. Apotex (Fed. Cir. 2008) (non-precedential) Apotex filed an abbreviated new drug application (ANDA) to begin making a generic version of the osteoporosis drug FOSAMAX. The drug brought in over $3 billion in 2007. Merck sued for infringement and... (original story)
Posted from Patent Law Blog (Patently-O) 33 days ago
Patent Law : News
Merck v. Apotex (Fed. Cir. 2008) (non-precedential) Apotex filed an abbreviated new drug application (ANDA) to begin making a generic version of the osteoporosis drug FOSAMAX. The drug brought in over $3 billion in 2007. Merck sued for infringement and... (original story)